165 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
BMRN BioMarin Pharmaceutical Inc. $98.11 $17.42B N/A
Article Searches
FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review https://www.fool.com/investing/2020/02/20/fda-gives-biomarin-pharmaceuticals-hemophilia-gene.aspx?source=iedfolrf0000001 Feb 20, 2020 - The agency expects to make a decision by Aug. 21, 2020.
Codexis Is Chasing a Blockbuster Opportunity. Can It Compete With Gene Therapies? https://www.fool.com/investing/2020/01/28/codexis-is-chasing-a-blockbuster-rare-disease-can.aspx?source=iedfolrf0000001 Jan 28, 2020 - The company is developing a novel enzyme-based treatment for phenylketonuria (PKU), but it faces growing competition from potentially curative gene therapies.
BMRN: BMO Capital Markets starts at Market Perform https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=UD20200127164506 Jan 27, 2020 - BMO Capital Markets issues rating change for BMRN
3 Top Biotech Picks for 2020 https://www.fool.com/investing/2020/01/20/3-top-biotech-picks-for-2020.aspx?source=iedfolrf0000001 Jan 20, 2020 - These stocks could thump the broader markets this year.
BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy https://www.fool.com/investing/2020/01/16/biomarin-considers-3-million-price-tag-for-new-hem.aspx?source=iedfolrf0000001 Jan 16, 2020 - If approved, Valrox could become the most expensive drug in the world.
BioMarin to Begin Early-Stage Study on Gene Therapy for PKU http://www.zacks.com/stock/news/717131/biomarin-to-begin-early-stage-study-on-gene-therapy-for-pku?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-717131 Jan 14, 2020 - BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.
BioMarin Files BLA for Gene Therapy to Treat Hemophilia A http://www.zacks.com/stock/news/685807/biomarin-files-bla-for-gene-therapy-to-treat-hemophilia-a?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-685807 Dec 24, 2019 - BioMarin (BMRN) submits a BLA in the United States for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal http://www.zacks.com/stock/news/655819/4-solid-gene-therapy-buyout-bets-post-audentes-astellas-deal?cid=CS-ZC-FT-analyst_blog|industry_focus-655819 Dec 05, 2019 - Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
REGN or BMRN: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/645048/regn-or-bmrn-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-645048 Nov 28, 2019 - REGN vs. BMRN: Which Stock Is the Better Value Option?
BMRN: Barclays ups to Overweight https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=UD20191127082510 Nov 27, 2019 - Barclays issues rating change for BMRN

Pages: 123456...17

Page 1>